Literature DB >> 18245661

Alterations in creatine kinase, phosphate and lipid values in patients with chronic myeloid leukemia during treatment with imatinib.

Anna Franceschino, Lucia Tornaghi, Valerie Benemacher, Sarit Assouline, Carlo Gambacorti-Passerini.   

Abstract

Imatinib, the treatment of choice for chronic myeloid leukemia, is generally well tolerated. We present here data from a retrospective analysis on metabolic abnormalities occurring during therapy which show increased creatine kinase, inverse creatine kinase-phosphate correlation, cholesterol and triglyceride values.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18245661     DOI： 10.3324/haematol.11680

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


  9 in total

1.  Serum creatine kinase increase in patients treated with tyrosine kinase inhibitors for solid tumors.

Authors:  Antoine Adenis; Olivier Bouché; François Bertucci; Elsa Kalbacher; Charles Fournier; Philippe Cassier; Olivier Collard; Jacques-Olivier Bay; Antoine Italiano; Christine Chevreau; Stéphanie Clisant; Andrew Kramar; Jean-Yves Blay; Nicolas Penel
Journal:  Med Oncol       Date:  2012-03-24       Impact factor: 3.064

2.  Cabozantinib-induced serum creatine kinase elevation and musculoskeletal complaints.

Authors:  Sarah E Stump; Young E Whang; Daniel J Crona
Journal:  Invest New Drugs       Date:  2018-06-28       Impact factor: 3.850

3.  Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome-positive chronic myeloid leukemia patients with resistance or intolerance to imatinib.

Authors:  Jorge E Cortes; Hagop M Kantarjian; Tim H Brümmendorf; Dong-Wook Kim; Anna G Turkina; Zhi-Xiang Shen; Ricardo Pasquini; H Jean Khoury; Steven Arkin; Angela Volkert; Nadine Besson; Richat Abbas; Junyuan Wang; Eric Leip; Carlo Gambacorti-Passerini
Journal:  Blood       Date:  2011-08-24       Impact factor: 22.113

Review 4.  Alterations in cellular metabolisms after Imatinib therapy: a review.

Authors:  Veerandra Kumar; Priyanka Singh; Sonu Kumar Gupta; Villayat Ali; Malkhey Verma
Journal:  Med Oncol       Date:  2022-05-16       Impact factor: 3.064

5.  Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failure.

Authors:  H Jean Khoury; Jorge E Cortes; Hagop M Kantarjian; Carlo Gambacorti-Passerini; Michele Baccarani; Dong-Wook Kim; Andrey Zaritskey; Athena Countouriotis; Nadine Besson; Eric Leip; Virginia Kelly; Tim H Brümmendorf
Journal:  Blood       Date:  2012-02-27       Impact factor: 22.113

6.  Chronic myeloid leukemia patients sensitive and resistant to imatinib treatment show different metabolic responses.

Authors:  Jiye A; Sixuan Qian; Guangji Wang; Bei Yan; Sujiang Zhang; Qing Huang; Lingna Ni; Weibin Zha; Linsheng Liu; Bei Cao; Ming Hong; Hanxin Wu; Hua Lu; Jian Shi; Mengjie Li; Jianyong Li
Journal:  PLoS One       Date:  2010-10-08       Impact factor: 3.240

7.  Imatinib mesylate (Gleevec) in the treatment of diffuse cutaneous systemic sclerosis: results of a 1-year, phase IIa, single-arm, open-label clinical trial.

Authors:  Robert F Spiera; Jessica K Gordon; Jamie N Mersten; Cynthia M Magro; Mansi Mehta; Horatio F Wildman; Stacey Kloiber; Kyriakos A Kirou; Stephen Lyman; Mary K Crow
Journal:  Ann Rheum Dis       Date:  2011-03-11       Impact factor: 19.103

Review 8.  European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia.

Authors:  J L Steegmann; M Baccarani; M Breccia; L F Casado; V García-Gutiérrez; A Hochhaus; D-W Kim; T D Kim; H J Khoury; P Le Coutre; J Mayer; D Milojkovic; K Porkka; D Rea; G Rosti; S Saussele; R Hehlmann; R E Clark
Journal:  Leukemia       Date:  2016-04-28       Impact factor: 11.528

9.  The BCR-ABL1 Inhibitors Imatinib and Ponatinib Decrease Plasma Cholesterol and Atherosclerosis, and Nilotinib and Ponatinib Activate Coagulation in a Translational Mouse Model.

Authors:  Marianne G Pouwer; Elsbet J Pieterman; Lars Verschuren; Martien P M Caspers; Cornelis Kluft; Ricardo A Garcia; Jurjan Aman; J Wouter Jukema; Hans M G Princen
Journal:  Front Cardiovasc Med       Date:  2018-06-12
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.